Results 81 to 90 of about 211,317 (295)

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

open access: yesAdvanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang   +4 more
wiley   +1 more source

Adropin: An endocrine link between the biological clock and cholesterol homeostasis [PDF]

open access: yes, 2014
This article explores two translation models circling around the key issue “equivalence” in translation studies. They are the Jerome Model and the Horace Model. They differentiate from each other in the aspects of the translating priorities and purposes,
Rao, D. C, et al,
core   +4 more sources

Identification of lipoprotein-binding proteins in rat liver Golgi apparatus membranes

open access: yesJournal of Lipid Research, 1988
The low density lipoprotein (LDL) receptor has been shown to be a plasma membrane glycoprotein responsible for the cellular binding and endocytosis of plasma lipoproteins.
J C Harrison, L L Swift, V S LeQuire
doaj   +1 more source

Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? [PDF]

open access: yes, 2017
Data from basic science experiments is overwhelmingly supportive of the causal role of immune-inflammatory response(s) at the core of atherosclerosis, and therefore the theoretical potential to manipulate the inflammatory response to prevent ...
Abbas   +173 more
core   +2 more sources

Extracellular Vesicles Modulation by an Adiponectin Receptor Agonist Provides Cardioprotection for Myocardial Ischemic Injury

open access: yesAdvanced Healthcare Materials, EarlyView.
This study demonstrates that ALY688, a drug mimicking the heart‐protective hormone adiponectin, reduces myocardial ischemia injury. ALY688 increases the production of extracellular vesicles, which carry protective cargo including adiponectin itself.
Jialing Tang   +13 more
wiley   +1 more source

Evolving targets for lipid‐modifying therapy

open access: yesEMBO Molecular Medicine, 2014
The pathogenesis and progression of atherosclerosis are integrally connected to the concentration and function of lipoproteins in various classes. This review examines existing and emerging approaches to modify low‐density lipoprotein and lipoprotein (a),
Rose Q Do   +2 more
doaj   +1 more source

CORE: Cholesterol Altered Lipid Nanoparticles for Splenic Expression of mRNA Payloads

open access: yesAdvanced Healthcare Materials, EarlyView.
In this paper researchers introduce CORE LNPs, a new class of lipid nanoparticles engineered to redirect mRNA expression away from the liver and into the spleen, a key immune organ. By combining chemical design with computational tools, they created cholesterol analogs that enable precise spleen‐targeted expression, providing greater applications for ...
Eshan A. Narasipura   +4 more
wiley   +1 more source

Immunohistochemical Labeling of Low-Density Lipoprotein Receptor and Scavenger Receptor Class B Type 1 Are Increased in Canine Lymphoma

open access: yesFrontiers in Veterinary Science, 2019
Altered lipid metabolism is a well-documented hallmark of neoplastic transformation and impacts disease progression. Two major lipoprotein receptors, the low-density lipoprotein receptor (LDL-R) and scavenger receptor class B, type 1 (SR-BI) are ...
Kristina Ceres   +4 more
doaj   +1 more source

Serum cholesterol levels in neutropenic patients with fever [PDF]

open access: yes, 2002
Hypocholesterolemia, which often accompanies infectious diseases has been suggested to serve as a prognostic marker in hospitalized patients. Even though patients with chemotherapyinduced leukopenia are at high risk of infection and mortality, only ...
Alvarez C   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy